CIPLA USA
CIPLA USA is the United States commercial subsidiary of Cipla Limited, an Indian-headquartered multinational pharmaceutical company. It operates a dedicated US-market presence via its domain usa.cipla.com. Specific product, customer, and revenue details are not documented in the available input.
- Company typePrivate
- Founded-
- HeadquartersWarren, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What CIPLA USA does
CIPLA USA is the United States commercial arm of Cipla Limited, an Indian-headquartered multinational pharmaceutical company. Its online presence is established at the domain usa.cipla.com, signaling a dedicated US-market go-to-market operation. No further operational detail — product portfolio, therapeutic categories, distribution channels, manufacturing footprint, or commercial strategy — is documented in the supplied source material.
The entity operates as a subsidiary rather than an independent US pharmaceutical company, implying that its product strategy, pricing, pipeline access, and regulatory posture are likely coordinated with the parent organization. As a US subsidiary of a major Indian generics manufacturer, CIPLA USA would conventionally serve US customers across generic prescription pharmaceuticals, respiratory, HIV, oncology, and other therapeutic areas where the parent has documented global franchises — though the supplied source data does not explicitly confirm any of these categories.
The business model, revenue mechanics, customer segmentation (wholesalers, retail pharmacy chains, hospital systems, government payers), and pricing structure are not documented in the input. The available evidence is limited to the entity name, its US web domain, and a single source identifier, which is insufficient to characterize pricing models, go-to-market motions, or revenue composition at the subsidiary level. Any inference beyond the basic US-subsidiary identity would constitute fabrication and is therefore excluded.
CIPLA USA firmographics
Firmographics- Name
- CIPLA USA
- Website
- https://ciplausa.com
- Company type
- Private
- Headcount range
- 1,001–5,000 employees
- Short description
- CIPLA USA is the United States commercial subsidiary of Cipla Limited, an Indian-headquartered multinational pharmaceutical company. It operates a dedicated US-market presence via its domain usa.cipla.com. Specific product, customer, and revenue details are not documented in the available input.
- Ownership category
- akta.pro rank
Where CIPLA USA is headquartered
LocationHeadquarters
- HQ city
- Warren
- HQ country
- United States
- HQ region
- North America
Markets served
CIPLA USA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Marketing or Sales
CIPLA USA product offering
Product offeringCore offering
CIPLA USA functions as the United States commercial subsidiary of Cipla Limited, an Indian multinational pharmaceutical company. The entity supports distribution and sale of the parent company's pharmaceutical portfolio in the US market. Specific product catalog, therapeutic areas, and service details are not disclosed in the available source content, which references only the company website URL.
Differentiator
Problem solved
Functional benefit
Companies that use CIPLA USA
Customer profileIdeal customer profiles1 record
CIPLA USA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CIPLA USA competitors and assessment
Company assessmentDirect peers
- Apotex: Canadian-headquartered generic pharmaceutical manufacturer with a sizable US business. Apotex competes with CIPLA USA in oral generics and has similar cost-driven economics.
- Viatris (formerly Mylan): Global generics powerhouse with a substantial US franchise formed via the Mylan-Upjohn merger. Viatris competes head-to-head with CIPLA USA in oral solids, injectables, and complex generics across the same US distribution channels.
- Sun Pharmaceutical Industries: India's largest pharmaceutical company with a significant US generic and specialty business (Taro Pharmaceuticals). A direct Indian-peer comparable to CIPLA USA in scale and US market positioning.
- Dr. Reddy's Laboratories: Indian pharma major with a long-established US generics presence. Competes with CIPLA USA in oral solids, injectables, and biosimilars, with comparable India-based cost structure and regulatory profile.
- Lupin Pharmaceuticals: US arm of Indian pharma major Lupin, with established US generic and specialty franchises. Directly comparable to CIPLA USA in therapeutic focus (respiratory, cardiovascular, CNS) and distribution strategy.
- Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical manufacturer with strong India manufacturing linkages through its AvKARE and Kashiv acquisitions. Comparable to CIPLA USA across generic injectables, oral solids, and specialty.
- Aurobindo Pharma USA: US subsidiary of Indian pharma major Aurobindo Pharma and one of the largest Indian-owned generic suppliers in the US. Highly comparable to CIPLA USA in product mix, customer base, and India-cost manufacturing model.
- Zydus Pharmaceuticals USA: US subsidiary of Indian pharma major Zydus Cadila with broad generic portfolio and transdermal specialty business. Closely comparable to CIPLA USA in scope, customer channels, and Indian-pharma cost model.
Broad incumbents
- Teva Pharmaceutical Industries: The largest generic drug manufacturer globally and dominant US generic supplier. Teva competes with CIPLA USA across virtually every therapeutic category and channel, and serves as the scale benchmark for US generic market position.
- Sandoz (Novartis generics division): Major global generic manufacturer spun out of Novartis. Sandoz is a top-three US generic player and a direct competitor to CIPLA USA across small molecules and biosimilars.
Market position
Strengths3 records
Weaknesses3 records
Key risks3 records
Key highlights3 records
Customer concentration
CIPLA USA social profiles
Digital presenceCIPLA USA financial estimates
Financial estimateRevenue estimate
Valuation estimate
CIPLA USA leadership team
Management profileNumber of profiles
CIPLA USA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CIPLA USA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CIPLA USA
What does CIPLA USA do?
CIPLA USA functions as the United States commercial subsidiary of Cipla Limited, an Indian multinational pharmaceutical company. The entity supports distribution and sale of the parent company's pharmaceutical portfolio in the US market. Specific product catalog, therapeutic areas, and service details are not disclosed in the available source content, which references only the company website URL.
When was CIPLA USA founded?
CIPLA USA was founded in -1. It employs 1,001 to 5,000 people.
Where is CIPLA USA based?
CIPLA USA is headquartered in Warren, United States, in the North America region.
Who are CIPLA USA's main competitors?
Direct peers on record are Apotex, Viatris (formerly Mylan), Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Lupin Pharmaceuticals, Amneal Pharmaceuticals, Aurobindo Pharma USA and Zydus Pharmaceuticals USA. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis generics division).
Does CIPLA USA have an API?
No public API is recorded for CIPLA USA.